ReviewClinical and experimental nephrology2014
Apolipoprotein E mutations: a comparison between lipoprotein glomerulopathy and type III hyperlipoproteinemia.
Review in Clinical and experimental nephrology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 34 citations in OpenAlex.
- Effect of High-Salt Diet on Memory and Behavior in Mice Expressing Human Apolipoprotein Epsilon-4 (APOE4) Allele.NeuroSci · 2026Article
- Lipoprotein glomerulopathy with a novel apolipoprotein E variant, APOE Kanto (Asp 151dup).CEN case reports · 2025Article
- Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features.Journal of atherosclerosis and thrombosis · 2025Review
- A case report of youth-onset lipoprotein glomerulopathy with APOE Chicago mutation.BMC nephrology · 2024Article
- Apolipoprotein E-associated Lipoprotein Glomerulo-tubulopathy.Internal medicine (Tokyo, Japan) · 2023Article
- The Role of ApoE Expression and Variability of Its Glycosylation in Human Reproductive Health in the Light of Current Information.International journal of molecular sciences · 2021Review
- Lipoprotein glomerulopathy induced by ApoE Kyoto mutation in ApoE-deficient mice.Journal of translational medicine · 2021Article
- Alcohol Drinking, Apolipoprotein Polymorphisms and the Risk of Cardiovascular Diseases.Current neurovascular research · 2021Review
- Clinical and genetic analysis of lipoprotein glomerulopathy patients caused by APOE mutations.Molecular genetics & genomic medicine · 2020Article
- The Genetic Variability ofGenes · 2019Review
- The impact of APOE genotype on survival: Results of 38,537 participants from six population-based cohorts (E2-CHARGE).PloS one · 2019Article
- Thermodynamic destabilization and aggregation propensity as the mechanism behind the association of apoE3 mutants and lipoprotein glomerulopathy.Journal of lipid research · 2018Article
- The Novel Apolipoprotein E Mutation ApoE Chengdu (c.518T＞C, p.L173P) in a Chinese Patient with Lipoprotein Glomerulopathy.Journal of atherosclerosis and thrombosis · 2018Article
- Glomerular Lesions in Proteinuric Miniature Schnauzer Dogs.Veterinary pathology · 2017Article
- Apolipoprotein E - A Multifunctional Protein with Implications in Various Pathologies as a Result of Its Structural Features.Computational and structural biotechnology journal · 2017Review
- Hyperlipoproteinemia type 3: the forgotten phenotype.Current atherosclerosis reports · 2014Review
- Pathogenesis, histopathologic findings and treatment modalities of lipoprotein glomerulopathy: A review.Jornal brasileiro de nefrologiaReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Apolipoprotein E (ApoE) serves as a ligand for the low-density lipoprotein (LDL) receptor and cell surface receptors of the LDL receptor gene family. More than 10 different causative apoE mutations associated with lipoprotein glomerulopathy (LPG) have been reported. ApoE polymorphisms including three common phenotypes (E2, E3, E4), and a variety of rare mutations can affect blood cholesterol and triglyceride levels. The N-terminal domain of apoE is folded into a four-helix bundle of amphipathic α-helices, and contains the receptor-binding domain in which most apoE mutations that cause LPG or dominant mode of type III hyperlipoproteinemia (HL) are located. No single apoE mutation has been reported that causes both LPG and the dominant mode of type III HL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.